Format

Send to

Choose Destination
Adv Ther. 2018 Jan;35(1):5-11. doi: 10.1007/s12325-017-0655-z. Epub 2017 Dec 28.

An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat.

Author information

1
Lerin Drug Co. Inc., New York, NY, USA. kimberly.anne.becker@gmail.com.
2
St. John's University, Jamaica, NY, USA.

Abstract

This article reviews an emerging therapeutic agent, which is currently in phase III development for the treatment of anemia secondary to chronic kidney disease, covering promising phase II results, drug characteristics, and the current phase III trials, which, if approved, may significantly impact the management of anemia in this patient population.

KEYWORDS:

Anemia; Chronic kidney disease; Daprodustat; Dialysis; Erythropoietin-stimulating agent; HIF-inhibitor; Hematology; Hemoglobin; Nephrology; Non-dialysis

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center